ARTICLE | Company News

Agios jumps on prospect of Phase I data

September 26, 2014 4:18 PM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) was up $10.31 (19%) to $63.76 on Friday on news that Phase I data for AG-120 will be announced at a late-breaking oral presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on Nov. 19.

Agios did not reveal any data in its announcement. In March, the biotech began the Phase I trial of the inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) in patients with advanced hematologic malignancies. ...